A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
Sander Palit(The Netherlands Cancer Institute), Michiel S. van der Heijden(The Netherlands Cancer Institute)
Cited by 17
Related Papers
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
|Nature Medicine|2020|395
The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer
|Frontiers in Immunology|2021|40
TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
|eLife|2019|38